Evommune, Inc. (EVMN)
13.67
-0.35
(-2.50%)
USD |
NYSE |
Aug 24, 16:00
13.66
-0.01
(-0.07%)
After-Hours: 20:00
Evommune Total Assets (Quarterly) : 301.95M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 301.95M |
| March 31, 2026 | 322.46M |
| December 31, 2025 | 224.95M |
| Date | Value |
|---|---|
| September 30, 2025 | 84.54M |
| June 30, 2025 | 96.21M |
| March 31, 2025 | 56.02M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | 368.35M |
| Mineralys Therapeutics, Inc. | 667.85M |
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 24.36M |
| Shareholders Equity (Quarterly) | 277.59M |
| Debt to Equity Ratio | 0.0311 |
| Current Ratio | 11.68 |
| Net Debt Paydown Yield | 7.65% |